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Introduction
Thrombosis is a major contributor to disability and mor-
tality worldwide and is estimated to be the cause of one in
four deaths [1]. It is the pathology responsible for trig-
gering acute myocardial infarction (AMI) and ischemic
stroke, and is the primary cause of venous thromboem-
bolism. The pathogenesis has been well-studied starting
with Virchow more than 150 years ago [2], and its pre-
vention by anti-thrombotic drugs has made much progress,
culminating most recently in the approval of new oral an-
ticoagulants which are specific inhibitors of thrombin or
factor Xa.
By contrast, treatment by thrombolysis, the only phar-
macological means available, has remained at a near
standstill since Genentech first applied for FDA approval of
tissue plasminogen activator (tPA) in 1983. A replacement
for streptokinase (SK) had been long-sought, but after early
successes in AMI, tPA use has since been on the decline.
Instead, percutaneous coronary intervention (PCI) has
become the treatment of choice in AMI, despite its tech-
nical, time-consuming, and costly demands. Pre-treatment
with tPA to hasten coronary reperfusion, so-called fa-
cilitated PCI, was found to increase PCI complications
including intracranial hemorrhage (ICH) making the two
incompatible [3]. In ischemic stroke, tPA has been esti-
mated to be used in only 2–5 % of patients over-all [4], and
in pulmonary embolism, bleeding and stroke complications
limited its use to the minority of patients with hemody-
namic decompensation [5].
The recent trend in stroke has also begun to favor the
use of endovascular devices with three major trials in is-
chemic stroke published in the first 2 months of 2015 in the
NEJM [6–8]. In this same period, a clinical trial of cathe-
ter-directed ultrasound was also published which showed a
significant acceleration of the thrombolysis rate by this
method [9].
These device reperfusion techniques require bringing
the patient to a qualified facility which inevitably consumes
precious time for conditions in which ‘‘minutes are my-
ocardium or neurons.’’ An optimal treatment for these
time-sensitive conditions can only be one that can be
brought to the patient and is easily and safely administered.
The resort to alternative methods is a reflection on the
inadequacy of current thrombolysis, a problem that was
foretold by the results with tPA in major clinical trials.
A brief review of thrombolysis with tPA
TPA was the first fibrin-specific thrombolytic [10] and
replaced SK, which was non-specific, causing extensive
hematological side effects, and which was an indirect
plasminogen activator. By contrast, tPA is a direct activator
and one that is strongly promoted by fibrin to which it has a
high affinity [11]. In the same year, this property was
shown to be sufficient to purify tPA directly from human
plasma in a single step [12].
In 1983, tPA was successfully produced by recombinant
technology by Genentech [13], and AMI was selected as
the first disease target. It was anticipated that because of its
fibrin-specific mode of action, tPA would prove far more
effective than SK, as also suggested by preliminary trials
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[14]. However, their difference turned out to be so mar-
ginal that it required an unprecedented total of 94,720
patients to arrive at a statistically significant p value in
comparative clinical trials.
Summary of the three mega trials of tPA versus SK
in AMI
1. GISSI-2 [15]
In a multicenter trial, 12,490 patients were randomized
to either single-chain tPA (100 mg infused iv over 3 h)
or a standard dose of SK. No difference in the 30 days
death rate was found, which was 9 % for tPA and
8.6 % for SK. The incidence of congestive heart fail-
ure, the second endpoint, was also not different. The
complication rate of stroke (1.1 and 0.9 % for tPA and
SK respectively) and major bleeding (0.5 and 1 %)
were also similar.
2. ISIS-3 [16]
A total of 41,229 patients were randomized to standard
doses of double chain tPA (Duteplase), SK, or
anisoylated SK (APSAC). All patients received aspirin
and half of each group received sc heparin starting at
4 h post thrombolysis. The outcome of the study was
similar to that of the previous one with a 35 days
mortality of 10.3 % for tPA, 10.6 % for SK, and
10.5 % for APSAC. A significant excess of total stroke
with tPA was, however, found, being 1.39 % for tPA
and 1.04 % for SK (p\ 0.01).
Once again, no explanation for the surprising lack of
clinical benefit from tPA over SK was offered.
3. The GUSTO study [17]
The final multinational study was with 42,021 patients
divided into four groups, two with SK plus either sc or
iv heparin and two with tPA and iv heparin, in one of
which the tPA was administered by a new accelerated
regimen. Only in the group given tPA by the accel-
erated regimen, was there a statistically significant
difference found. The 30 day mortality in this group
was 6.3 % with tPA and 7.2 % for SK (p\ 0.001).
The ICH incidence again was significantly (p = 0.03)
higher with tPA than SK, as was the incidence of
‘‘moderate or worse’’ bleeding (p = 0.02).
The finding of a significant difference in the result from
this trial was met with some skepticism. In a commentary
by three prominent experts, it was concluded that there
was ‘‘at most, a small absolute difference… in both lives
saved and major complications between tPA and SK’’
[18]. The GUSTO trial results also underwent a Bayesian
analysis which found them to be inconclusive and that
‘‘the clinical superiority of tPA over SK remains uncer-
tain’’ [19].
Nevertheless, tPA was given approval for AMI treat-
ment after the GUSTO trial and tPA or one of its longer
half-life derivatives, has remained the thrombolytic of
choice ever since becoming essentially synonymous with
thrombolysis. In 1996, tPA was also approved for the
treatment of ischemic stroke.
The unprecedented number of patients that were re-
quired to gain approval for a new thrombolytic had its
adverse consequences. The experience not only discour-
aged further investment in thrombolysis by industry, but it
also dampened scientific interest. It was believed that the
trials showed that all activators must be more or less
comparable and that the difference between a fibrin-
specific and a non-specific activator was less important
than had been believed. It was as if the limits of what was
possible with thrombolysis had been reached.
In retrospect, a crucial alternative interpretation was
missed. This was that the very nature of tPA’s fibrin-
specific mode of action limited its fibrinolytic effect and
conversely, that it was the non-specific mode of action of
SK that gave it an unrestricted plasminogen activating ef-
fect which gave it a comparable efficacy. The activators’
net effect was similar but for very different reasons. The
more limited fibrinolytic effect of tPA had been previously
implied by the finding that its fibrin-dependent plasmino-
gen activation was different and complementary to that of
the other natural plasminogen activator prourokinase
(proUK) [20].
The biological pathway of fibrinolysis and its
lessons
Since all therapeutic thrombolysis utilizes the endogenous
plasminogen-plasmin pathway, endogenous fibrinolysis
provides a useful guide to its function and utilization. For
hemostasis, fibrin must be sufficiently stiff to serve as a
meshwork to prevent bleeding but at the same time it must
be capable of being lysed when vital blood flow is threat-
ened by the same meshwork. Plasmin is responsible for
fibrinolysis and does so by cleaving the polymer into two
major soluble fibrin degradation products [21], a remark-
ably efficient solution to the problem. Plasminogen, the
proenzyme precursor of plasmin, is available in relatively
high abundance in plasma (*2 lM), more than sufficient
for its therapeutic utilization.
Plasmin is relatively non-specific and hydrolyzes other
substrates including three clotting factors, and can induce a
hemorrhagic diathesis. To make it more fibrin-specific, two
additional factors have evolved. First plasmin(ogen) targets
fibrin by binding directly to certain lysine binding sites
[22]. This both targets and promotes its fibrinolytic ac-
tivity. Unbound plasmin, by contrast, induces little
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fibrinolysis, as evidenced by microplasmin which has no
fibrin binding domains and induces little fibrin degradation
but retains a full fibrinogenolytic effect [23]. Second, the
two endogenous activators of plasminogen, tPA and
proUK, have high specificities for fibrin-bound plasmino-
gen over that which is not bound. As a result, the biological
system is highly fibrin specific and proteolysis is addi-
tionally limited to the fibrin clot environment by certain
inhibitors in the ambient plasma. Importantly, the en-
dogenous system utilizes both activators for fibrinolysis
rather than just one as has been the custom in therapeutic
thrombolysis.
The sequential and complementary mechanisms
of fibrin-dependent plasminogen activation by tPA
and proUK
When intravascular thrombosis occurs, tPA stored in the
vessel wall at that site is released, binds to the thrombus,
and initiates fibrin degradation. This is mediated by tPA’s
high fibrin affinity for a specific site on the D-domain of
intact fibrin [11, 24] that is adjacent to fibrin-bound plas-
minogen. This ternary complex promotes plasminogen
activation by tPA more than 1000-fold [25] and efficiently
initiating degradation of the fibrin surface. This creates new
plasminogen binding sites [26], and plasminogen bound to
these new sites is activated preferentially by proUK and its
activated form urokinase (UK). Specifically, proUK has a
high substrate affinity for plasminogen bound to a triple
carboxyterminal lysine high affinity site on the fibrin
E-domain of degraded fibrin [27]. Plasminogen at this site
undergoes a conformational change which promotes
proUK’s intrinsic activity more than 250-fold, giving it an
activity equivalent to that of UK [28]. A similar promotion
of proUK’s intrinsic activity by plasminogen bound to
solid-phase fibrin after its degradation was also shown in
another study [29].
This activation of plasminogen by proUK is accompa-
nied by reciprocal activation of proUK by plasmin [30] that
is associated with a hypercatalytic transitional state be-
tween proUK and UK [31]. Thereafter, UK activates the
remaining plasminogen on degraded fibrin. The activation
of proUK during lysis adds to its fibrinolytic effect as il-
lustrated by a study with an inactivatable, plasmin-resistant
mutant proUK which was 100-fold less effective in clot
lysis [32]. ProUK/UK, therefore, has a dual plasminogen-
activating function in fibrinolysis. By contrast, tPA un-
dergoes no functional change since its one and two-chain
forms have similar fibrinolytic properties [33]. This
relatively more limited effect of tPA was observed in an
earlier study in which the rates of fibrin-specific clot lysis
(\10 % fibrinogenolysis) in a plasma milieu by tPA and
proUK were compared. The lysis rate by proUK was
consistently twice that of tPA [34], a finding which indi-
cated that proUK activated twice as many fibrin-bound
plasminogens.
These findings suggest that there are a total of three
different plasminogen binding sites available on fibrin, one
on intact fibrin activated by tPA and two additional ones on
degraded fibrin activated by proUK and UK, consistent
with the 2:1 ratio of their lysis rates. This same number of
plasminogens was documented in a previous study in
which the molar amounts of plasminogen on intact and
degraded fibrin were measured. There were 23.4 nmol/l of
plasminogen found on intact fibrin and 61.9 nmol/l on
degraded fibrin for a total of three [35].
The fibrinolytic activities of tPA and proUK are,
therefore, promoted by different fibrin domains which are
the D and E domains respectively. This was also shown in a
kinetic study with soluble fibrin fragments D and E in
which plasminogen activation was measured. Plasminogen
activation by tPA was promoted only by fragment D,
whereas that by proUK was promoted only by fibrin frag-
ment E [36], making the activators complementary in their
fibrin-dependent plasminogen activating effects.
Clinical implications
These fibrinolytic differences also affect the etiology of the
hemorrhagic side effects of tPA and proUK. Hemostatic
fibrin, being protected from fibrinolytic degradation, re-
mains intact and consequently is much more vulnerable to
lysis by tPA than by proUK. This is not a problem
physiologically because tPA normally circulates as an in-
active complex with its inhibitor, plasminogen activator
inhibitor-1 (PAI-1), but PAI-1 is at far too low a concen-
tration for therapeutic amounts of tPA, leaving hemostatic
fibrin unprotected. This explains the unexpected finding of
a significantly higher incidence of ICH by tPA than by non-
specific SK in the mega trials [16, 17]. The lysis of he-
mostatic fibrin by tPA was previously cited as the principle
cause [37, 38]. Therefore, bleeding is a direct consequence
of tPA’s mechanism of action of targeting intact fibrin to
initiate lysis, explaining also why its therapeutic doses need
to be limited.
This tPA effect was studied experimentally in a dog
model in which blood loss from standardized hemo-
statically sealed fresh injury sites was measured. Blood loss
by tPA was tenfold higher than that by proUK (mean 40 vs
4 ml, p = 0.026) at equivalent fibrinolytic doses [39], a
finding consistent with the differences in their mechanisms
of fibrin-dependent plasminogen activation.
The etiology of proUK’s bleeding side effects is quite
different. ProUK is vulnerable to conversion to UK at
therapeutic concentrations in plasma due to plasmin gen-
eration at these concentrations. UK compounds this
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problem by generating much more plasmin inducing a
hemorrhagic diathesis with degradation of clotting factors
like fibrinogen, as seen in the proUK clinical trials [40]. It
was for this reason that, proUK was denied marketing
approval, in Europe. To address this problem, a mutant
form of proUK was developed (see below).
Synergistic fibrinolysis by tPA and proUK in vitro
and in vivo
When tPA and proUK were used together versus either
activator alone, a synergistic effect was observed in clot
lysis experiments in a plasma milieu [41] which was at-
tributed to their complementary modes of action [20].
Nevertheless, the synergistic effect of tPA and proUK has
continued to remain controversial since it was contested by
other investigators [42].
The effect of a sequential combination was also
evaluated clinically in a multicenter study of patients with
AMI. In the PATENT trial, 101 patients were treated with a
small bolus of tPA followed by a modest infusion of proUK
[43]. The first 10 patients were given a 10 mg bolus which
turned out to be excessive. The remainder were given a
5 mg bolus of tPA (5 % of the standard dose) followed by
a proUK infusion of 40 mg/h (50 % of the standard rate)
for 90 min. A TIMI 2–3 coronary patency rate of 77 % and
a TIMI 3 patency rate of 60 % were obtained, with no
reocclusions or strokes and a mortality of 1 %. The patency
rate obtained was comparable to that reported for the best
of the four groups in the GUSTO trial [44], in which the
mortality was 6.3 % with 1.5 % strokes [17].
Despite the success of the PATENT trial, no follow-up
study was possible since Farmitalia, the sponsor, was sold
soon after and proUK development ceased, and was dis-
continued by Gruenenthal a little later after their submis-
sion for marketing approval of proUK was denied due to
the UK bleeding complications.
The clinical experience with proUK in brief
ProUK, the native, precursor of UK, was first isolated from
human urine and identified to be a single-chain proenzyme
in 1981 [12, 45]. It was shown to have a fibrin-specific
mode of action, in contrast to UK, despite having no fibrin
clot affinity [46]. After several small clinical studies with
proUK for different indications, phase III clinical trials in
AMI were done with recombinant proUK from E. coli by
Gruenenthal [47, 48]. An efficacy comparable to that of
other activators was found but with a lower rate (0–5 %) of
rethrombosis and no hematological evidence of thrombin
generation [49], in contrast to tPA. However, at the
therapeutic concentrations of proUK used, its relatively
high intrinsic activity [50] induced systemic plasmin gen-
eration which converted proUK to UK, inducing extensive
(80–90 %) fibrinogenolysis [40]. As noted above, due to
this problem, marketing authorization for proUK was de-
nied by the European Medicines Agency in 1998, ‘‘on the
basis of the higher incidence of hemorrhagic strokes,’’ and
proUK development was terminated.
Since proUK had unique properties and therapeutic
potential, especially in combination with tPA, it was de-
cided to address the problem of its vulnerability to UK
conversion by recombinant technology.
Mutant proUK (HisproUK)
Structure–function studies revealed a flexible loop in the
catalytic domain of proUK with a charged residue (Lys
300) at its tip which was shown to be responsible for
proUK’s relatively high intrinsic activity [51]. By reducing
the charge at this position, the intrinsic activity could be
modulated [52]. A single site mutant (Lys300 ? His) was
eventually selected which had a fivefold lower intrinsic
activity but a preserved two-chain enzymatic activity and
other properties of proUK were also preserved. The His-
proUK mutant was stable in plasma at a fivefold higher
concentration than native proUK.
In a dog model, HisproUK induced effective lysis of
venous thromboemboli which was associated with sur-
prisingly little bleeding from hemostatic sites [53]. This
phenomenon was tested in a second dog study against an
arterial thrombus. HisproUK induced a vessel patency rate
equivalent to that of tPA, but with tenfold less blood loss
from fresh hemostatic sites than tPA [39], as also described
above. The low bleeding rate was related to a novel in-
hibitor complex between HisUK and plasma C1 esterase
inhibitor (C1INH) in the plasma of these dogs, which in-
hibited HisUK mediated side effects.
The C1INH effect
The same HisUK:C1INH inhibitor complex was found in
human plasma after incubation with HisUK. In clot lysis
studies in a plasmamilieu, C1INH inhibited fibrinogenolysis
by HisproUK without interfering with fibrinolysis [54].
Since C1INH is available as a pharmacological agent, clot
lysis experiments were done with supplemental C1INH
sufficient to double and triple its physiological concentra-
tion. At these higher concentrations, a maximum rate of clot
lysis by HisproUK could be induced without causing the
fibrinogen degradation, which otherwise accompanied such
doses [55]. The C1INH prevention of fibrinogenolysis, but
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not fibrinolysis, by HisproUK is a unique property for a
plasminogen activator.
C1INH is a relatively abundant (*250 lg/ml) plasma
inhibitor, whereas plasminogen activator inhibitor-1 (PAI-
1), the principal inhibitor of UK, is present only at a
nanogram concentration (21 ± 7 ng/ml). Since HisproUK
is activated to HisUK during clot lysis, it’s inhibition by
plasma C1INH helps prevent the bleeding complications
that occurred due to UK (see Fig. 1). Since C1INH is also
an acute phase reactant, it is apt to be present at higher
concentrations in patients with AMI, stroke or throm-
boembolism, so that supplemental C1INH is less likely to
be needed, especially at the lower HisproUK doses needed
with the synergistic combination.
Testing fibrinolytic synergy of tPA and HisproUK
In a clot lysis model in a plasma milieu, the dose of tPA or
HisproUK alone which induced the shortest clot lysis time
possible was established. Thereafter, the fractional dose
combination that gave a comparable lysis time was selected
and consisted of 3–6 % of the tPA dose combined with
40 % that of the HisproUK. These fractional doses were
almost identical to those of tPA and proUK in the clinical
PATENT trial, which were 5 and 40 %, as described
above. This similarity between the findings from this
in vitro study to those found clinically provided evidence
for the clinical relevance of the clot lysis model [56].
In the HisproUK clot lysis study, increasing the mini
dose of tPA in the combination had no effect on the lysis
time, a finding consistent with tPA’s fibrinolytic function
being limited to the initiation of lysis. The doses of tPA and
HisproUK in the synergistic combination caused no fib-
rinogenolysis, in contrast to that which was caused by the
doses need of either activator used alone to induce a similar
lytic effect [53].
Conclusions
Intravascular thrombosis remains a leading cause of death
and disability for which thrombolysis is the only pharma-
cological remedy. The thrombolytic, tPA, has become
essentially synonymous with thrombolysis but its use, or
that of one of its longer half-life derivates, has been de-
clining due to its inadequate efficacy in AMI, incom-
patibility with PCI, limited efficacy and risk of ICH in
ischemic stroke, and too high a bleeding risk for most
Fig. 1 Fibrinolysis by the sequential modes of action of tPA and
proUK or HisproUK: tPA binds (dashed line) to intact fibrin adjacent
to plasminogen(Plg1), forming a ternary complex and activating Plg1
to plasmin (Plm). This initiates fibrin degradation resulting in the
creation of new plasminogen binding sites on fibrin. Plg2 binds to a
high-affinity binding site on the fibrin E (FFE) domain, which induces
a special conformational shape change in Plg2 that enables it to be
activated by the intrinsic activity of HisproUK. This HisproUK:plas-
minogen complex results in Plm formation and the reciprocal
activation (double arrow) of HisproUK ? HisUK, associated with
a transitional state that is hypercatalytic. UK, being a non-specific
enzyme, then activates the remaining fibrin-bound plasminogen
(Plg3). The three Plm together complete fibrin degradation (thick
arrows) forming soluble fibrin degradation products (FDP). In the
Plasma Phase, when UK diffuses off the fibrin clot, if it is not
inhibited, it will activate plasma Plg to Plm, resulting in the
degradation of 3 clotting factors, among other side effects. When
HisproUK is used in place of proUK, this non-specific effect is
prevented due to HisUK being inhibited by C1INH, whose plasma
concentration is[1000-fold greater than that of the UK inhibitor
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patients with venous thromboembolism. Instead, intra-ar-
terial devices have become the treatment of choice in AMI
are becoming more frequently used in ischemic stroke as
well. The resort to these time-consuming methods to treat
very time-sensitive conditions is a reflection on the
inadequacy of current thrombolysis.
In retrospect, the conclusion that the results of the tPA
mega trials ‘‘should be taken as evidence that any mortality
differences… between different fibrinolytic regimens are
unlikely to be large’’ [16] was a misinterpretation. Instead,
the evidence suggests that it is the fibrin-specific mode of
action of tPA which restricted its plasminogen activation
thereby giving a non-specific activator like SK, with no
such restrictions, an efficacy that was essentially compa-
rable but for different reasons. Therefore, the impression of
comparability reflected the fibrinolytic limitations of tPA
monotherapy.
The biological plasmin-mediated pathway is the basis of
all therapeutic thrombolysis and in nature it utilizes both
plasminogen activators, tPA and proUK, in a sequential
combination rather than only one. Using this paradigm, a
synergistic thrombolytic effect was obtained from frac-
tional doses of the activators both in vitro as well as in a
clinical study of AMI.
The other activator, proUK, was unstable in plasma at
pharmacological concentrations and amore stable single site
substitution mutant was designed to replace it. Preclinical
testing showed that HisproUK was comparably synergistic
as proUK with a much reduced liability for bleeding com-
plications due to a unique property that its enzymatic form,
HisUK, was inhibited by C1INH in plasma.
The combination of mini-dose tPA followed by an infu-
sion of a moderate dose of HisproUK is expected to provide
more effective therapeutic thrombolysis with a significantly
lower risk of ICH, capable of administration without any
delay in stroke. Other indications include facilitated PCI,
and the treatment of venous thromboembolism.
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